These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26930181)

  • 21. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
    Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
    Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
    Kovatchev BP; Crean J; McCall A
    Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia.
    Heptulla RA; Rodriguez LM; Mason KJ; Haymond MW
    J Clin Endocrinol Metab; 2009 May; 94(5):1608-11. PubMed ID: 19190104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
    Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
    Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal effects of extra-virgin olive oil associated with lower postprandial glycemia in type 1 diabetes.
    Bozzetto L; Alderisio A; Clemente G; Giorgini M; Barone F; Griffo E; Costabile G; Vetrani C; Cipriano P; Giacco A; Riccardi G; Rivellese AA; Annuzzi G
    Clin Nutr; 2019 Dec; 38(6):2645-2651. PubMed ID: 30567626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
    Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pramlintide in the treatment of diabetes.
    Edelman SV; Darsow T; Frias JP
    Int J Clin Pract; 2006 Dec; 60(12):1647-53. PubMed ID: 17109671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
    King AB
    Diabetes Technol Ther; 2010 Feb; 12(2):105-8. PubMed ID: 20105039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes.
    Underland LJ; Ilkowitz JT; Katikaneni R; Dowd A; Heptulla RA
    J Diabetes Sci Technol; 2017 May; 11(3):602-610. PubMed ID: 28349708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postprandial glucose, insulin and incretin responses to different carbohydrate tolerance tests.
    Deng Y; Zhang Y; Zheng S; Hong J; Wang C; Liu T; Sun Z; Gu W; Gu Y; Shi J; Yao S; Wang W; Ning G
    J Diabetes; 2015 Nov; 7(6):820-9. PubMed ID: 25395350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
    Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
    Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
    J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ingestion of thermally oxidized sunflower oil decreases postprandial lipemia mainly in younger individuals.
    Manning PJ; Sutherland WH; Manning AE; de Jong SA; Berry EA
    Nutr Res; 2013 Sep; 33(9):711-8. PubMed ID: 24034570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.
    Andersen G; Meiffren G; Famulla S; Heise T; Ranson A; Seroussi C; Eloy R; Gaudier M; Charvet R; Chan YP; Soula O; DeVries JH
    Diabetes Obes Metab; 2021 Apr; 23(4):961-970. PubMed ID: 33336850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.
    Micheletto F; Dalla Man C; Kolterman O; Chiquette E; Herrmann K; Schirra J; Kovatchev B; Cobelli C
    Diabetes Technol Ther; 2013 Oct; 15(10):802-9. PubMed ID: 23865841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.
    Ceriello A; Lush CW; Darsow T; Piconi L; Corgnali M; Nanayakkara N; Frias JP; Maggs D
    Diabetes Metab Res Rev; 2008 Feb; 24(2):103-8. PubMed ID: 17694505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postprandial glucose fluxes and insulin sensitivity during exercise: a study in healthy individuals.
    Schiavon M; Hinshaw L; Mallad A; Dalla Man C; Sparacino G; Johnson M; Carter R; Basu R; Kudva Y; Cobelli C; Basu A
    Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E557-66. PubMed ID: 23820621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
    Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
    Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.